ENDRA Life Sciences Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $159.9K | $-1.3M | $-3.2M | $-1.6M | $-1.2M | $-1.0M | $-4.1M | $-2.4M |
| Depreciation & Amortization | $8.2K | $9.5K | $10.1K | $10.8K | $9.4K | $13.8K | $11.0K | $11.5K |
| Depreciation | $8.2K | $9.5K | $10.1K | $10.8K | $9.4K | $13.8K | $11.0K | $11.5K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $541.9K | $574.5K | $12.9K | $194.0K | $39.5K | $83.0K | $104.7K | $-36.8K |
| Net Cash from Operating Activities | $-927.6K | $-1.1M | $-1.6M | $-1.2M | $-1.1M | $-1.3M | $-1.5M | $-1.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $0 | $0 | $0 | $17.3K | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $2.2M | $450.0K | $-3.0M | $0 | $0 | $-17.3K | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.9M | $263.7K | $4.6M | $149.5K | $857.4K | $145.8K | $0 | $1.7K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | $-1.6M | $-1.2M | $-1.1M | $-1.3M | $-1.5M | $-1.7M |